Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Curr Ophthalmol Rep. 2024 Mar 24;12(2):13–22. doi: 10.1007/s40135-024-00322-5

Fig. 1.

Fig. 1

Structure of ADCs. There are three well-defined components: antibody, chemical linker, and cytotoxic payload. Of the current FDA-approved ADCs, all have IgG1 or IgG4 mAbs. Payloads, which either damage DNA or disrupt microtubule formation during mitosis, are linked to the mAb via a chemical linker, which are defined as cleavable or non-cleavable. Created with BioRender.com